These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 28179481)
1. Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481 [TBL] [Abstract][Full Text] [Related]
2. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564 [TBL] [Abstract][Full Text] [Related]
3. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443 [TBL] [Abstract][Full Text] [Related]
4. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells. Chen M; Mashima T; Oishi T; Muramatsu Y; Seto Y; Takamatsu M; Kawata N; Morino S; Nakamura A; Inaba S; Yuan X; Maruyama K; Suzuki M; Sato A; Yoshida H; Jang MK; Mizutani A; Takeuchi K; Yamaguchi K; Shirai F; Nagayama S; Katayama R; Seimiya H Br J Cancer; 2024 Jan; 130(1):151-162. PubMed ID: 37968472 [TBL] [Abstract][Full Text] [Related]
5. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase. Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752 [TBL] [Abstract][Full Text] [Related]
6. Evidence for tankyrases as antineoplastic targets in lung cancer. Busch AM; Johnson KC; Stan RV; Sanglikar A; Ahmed Y; Dmitrovsky E; Freemantle SJ BMC Cancer; 2013 Apr; 13():211. PubMed ID: 23621985 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells. Bao R; Christova T; Song S; Angers S; Yan X; Attisano L PLoS One; 2012; 7(11):e48670. PubMed ID: 23144924 [TBL] [Abstract][Full Text] [Related]
8. Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase. Jang MK; Mashima T; Seimiya H Mol Cancer Ther; 2020 Mar; 19(3):765-776. PubMed ID: 31907221 [TBL] [Abstract][Full Text] [Related]
9. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer. Mashima T; Taneda Y; Jang MK; Mizutani A; Muramatsu Y; Yoshida H; Sato A; Tanaka N; Sugimoto Y; Seimiya H Oncotarget; 2017 Jul; 8(29):47902-47915. PubMed ID: 28615517 [TBL] [Abstract][Full Text] [Related]
11. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Waaler J; Machon O; Tumova L; Dinh H; Korinek V; Wilson SR; Paulsen JE; Pedersen NM; Eide TJ; Machonova O; Gradl D; Voronkov A; von Kries JP; Krauss S Cancer Res; 2012 Jun; 72(11):2822-32. PubMed ID: 22440753 [TBL] [Abstract][Full Text] [Related]
12. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells. Ma L; Wang X; Jia T; Wei W; Chua MS; So S Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473 [TBL] [Abstract][Full Text] [Related]
13. BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer. Morino S; Mashima T; Shirai F; Nagayama S; Katayama R; Seimiya H Cancer Lett; 2024 Mar; 584():216632. PubMed ID: 38216082 [TBL] [Abstract][Full Text] [Related]
14. The Anti-Tumor Activity of Succinyl Macrolactin A Is Mediated through the β-Catenin Destruction Complex via the Suppression of Tankyrase and PI3K/Akt. Regmi SC; Park SY; Kim SJ; Banskota S; Shah S; Kim DH; Kim JA PLoS One; 2015; 10(11):e0141753. PubMed ID: 26544726 [TBL] [Abstract][Full Text] [Related]
15. Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition. Schatoff EM; Goswami S; Zafra MP; Foronda M; Shusterman M; Leach BI; Katti A; Diaz BJ; Dow LE Cancer Discov; 2019 Oct; 9(10):1358-1371. PubMed ID: 31337618 [TBL] [Abstract][Full Text] [Related]
18. Structure, Dynamics, and Functionality of Tankyrase Inhibitor-Induced Degradasomes. Thorvaldsen TE; Pedersen NM; Wenzel EM; Schultz SW; Brech A; Liestøl K; Waaler J; Krauss S; Stenmark H Mol Cancer Res; 2015 Nov; 13(11):1487-501. PubMed ID: 26124443 [TBL] [Abstract][Full Text] [Related]
19. Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells. Kulak O; Chen H; Holohan B; Wu X; He H; Borek D; Otwinowski Z; Yamaguchi K; Garofalo LA; Ma Z; Wright W; Chen C; Shay JW; Zhang X; Lum L Mol Cell Biol; 2015 Jul; 35(14):2425-35. PubMed ID: 25939383 [TBL] [Abstract][Full Text] [Related]
20. Discovery of a Novel Triazolopyridine Derivative as a Tankyrase Inhibitor. Ryu H; Nam KY; Kim HJ; Song JY; Hwang SG; Kim JS; Kim J; Ahn J Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]